| Followers | 47 |
| Posts | 10072 |
| Boards Moderated | 0 |
| Alias Born | 12/10/2009 |
Sunday, October 03, 2021 2:09:13 PM
Been watching this. The Merck pill has promise but I don't think the FDA will approve it. Pfizer bought and paid for Fauci and the FDA. If this pill is approved, that would cost Pfizer billions. Hope I'm wrong, just my opinion.
Recent MRK News
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/07/2026 11:00:59 AM
- Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration • Business Wire • 04/02/2026 10:50:00 AM
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens • Business Wire • 04/02/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:47:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:44:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:42:51 PM
- Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 • Business Wire • 04/01/2026 11:00:00 AM
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins • Business Wire • 03/30/2026 03:45:00 PM
- Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction • Business Wire • 03/29/2026 03:45:00 PM
- Enliven Therapeutics shares jump 28% after Merck’s $6.7 billion Terns acquisition announcement • IH Market News • 03/25/2026 02:05:57 PM
- Terns Pharma stock jumps on report of potential $6B takeover by Merck • IH Market News • 03/25/2026 10:52:24 AM
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) • GlobeNewswire Inc. • 03/25/2026 10:48:00 AM
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) • Business Wire • 03/25/2026 10:45:00 AM
- New Public Listings for Canadians Living with Pulmonary Arterial Hypertension • PR Newswire (Canada) • 03/24/2026 11:30:00 AM
- Nouvelles inscriptions de produits à la liste de médicaments provinciale destinées aux Canadiens atteints d'hypertension artérielle pulmonaire • PR Newswire (Canada) • 03/24/2026 11:30:00 AM
- FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs • Business Wire • 03/18/2026 08:30:00 PM
- Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026 • Business Wire • 03/17/2026 10:50:00 AM
- Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research • Business Wire • 03/16/2026 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 05:52:51 PM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (Canada) • 03/03/2026 02:00:00 PM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (US) • 03/03/2026 02:00:00 PM
- KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC) • Business Wire • 02/28/2026 03:05:00 PM
- WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) • Business Wire • 02/28/2026 03:00:00 PM
- KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer • Business Wire • 02/27/2026 03:15:00 PM
- KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery • Business Wire • 02/27/2026 03:00:00 PM

